Symetis has announced, in less than a year after the device was commercially launched, the Acurate neo/TF has been implanted in more than 1,000 patients. The company’s other valve, Acurate TA system, has achieved a number two position in its segment of the European transcatheter aortic valve implantation (TAVI).
A press release reports that the 1000th procedure was carried out at the Ferrarotto Hospital of the University of Catania, Italy, on September 15, 2015. Corrado Tamburino, head of Cardiology of the Ferrarotto Hospital, says: “With its stability during implantation and the resulting predictability of success, Acurate TF has really exceeded our expectations. The Acurate TF system scored high on all key parameters, such as procedural success, paravalvular leak, and pacemaker implant rate.”
According to the press release, Symetis’s Acurate Neo valve has been developed and approved for transfemoral procedures, which constitute approximately 85% of all TAVI procedures in the European market according to BIBA MedTech Insights, TAVI report Q2 2015. The device, the press release notes, complements the company’s successful transapical system, Acurate TA, which with a 21% market share has claimed a strong second place in the transapical segment of the European TAVI market. Together with Edwards Lifesciences and Medtronic, Symetis is the only company that provides TAVI valves for both transfemoral and transapical options for transcatheter aortic heart valve delivery.